TX-COGNITIVE-SPACE
6.7.2021 15:02:10 CEST | Business Wire | Press release
Cognitive Space today announced it has been selected to participate in the Amazon Web Services (AWS) Space Accelerator , a business support program for startups seeking to use AWS to help solve the biggest challenges in the space industry. This opportunity will support Cognitive Space efforts to revolutionize satellite operations by bringing the power of artificial intelligence and machine learning to mission operations and collection planning. Cognitive Space provides New Space organizations with sophisticated tools for optimizing revenue and performance yield as their satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005120/en/
New for 2021, the four-week AWS Space Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support in collaboration with Seraphim, one of the world’s leading investment groups focused exclusively on the space industry, who will provide business development and investment guidance.
Cognitive Space will rely on AWS Cloud infrastructure for its own Space-focused software products - including licensed services, underlying platform architecture, development & test environments, and AI/ML training and processing workloads. Cognitive Space will take advantage of AWS services for scalability, cost-effectiveness, security, reliability, and global reach.
“Being one of the few startups accepted into the AWS Space Accelerator is a great honor and we appreciate the confidence AWS has placed in us,” said Scott Herman, CEO of Cognitive Space. “We’re very excited about the mentoring opportunity that the accelerator provides to startups like ours, and we look forward to working closely with AWS and Seraphim as we build our company.” Guy de Carufel, CTO of Cognitive Space, added “We depend on Amazon Web Services to provide high-reliability and scalable infrastructure for the satellite operations services we deliver to our customers and partners, and we are eager to learn more from the AWS experts during the accelerator.”
As one of 10 companies chosen for this opportunity out of a field of approximately 200 startups, Cognitive Space will receive up to $100,000 in AWS Activate credit, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors.
“AWS looks forward to collaborating with our finalists to advance their inspiring vision for transforming how we understand, operate in, and benefit from space,” said Clint Crosier, director of the Aerospace and Satellite business at AWS. “Congratulations to our finalists, who were selected from hundreds of impressive startups from across the global space industry. The cloud is uniquely suited to spur the success of space companies in so many ways, and we are excited to help these companies achieve their biggest goals.”
Proposals were judged on several factors including the innovative and unique nature of the project, the overall value the solution will bring to the space industry, the creative application of AWS to solve problems, and the team’s ability to deliver on its specific mission.
For more information on the AWS Space Accelerator, visit https://seraphim.vc/aws/accelerator/ .
About Cognitive Space
Cognitive Space is developing advanced automation systems for the space industry with a particular focus on the software management of satellite constellations, including mission management, collection planning, communication link management, and modeling & simulation of future capabilities.
Our early focus is on orchestrated collection management for the explosion of new remote sensing constellations - multi-phenomenology, large-fleet constellations of small satellite sensors that offer unprecedented facility monitoring, activity monitoring, and pattern-of-life analysis for national security and commercial organizations with a global monitoring mission.
Cognitive Space is developing an AI-driven solution for near real-time dynamic mission planning for Low Earth Orbit (LEO) Satellites. By 2030, research analysts predict 15-20x growth in deployed satellites in service, from 3000 in 2021 to ~50,000 satellites in orbit. Satellite constellations are increasingly being tasked by government and commercial consumers for use cases including communications, agriculture, environmental protection, meteorology, navigation, national defense, and myriad other commercial, military and governmental use cases.
The Cognitive Space satellite constellation management platform allows operators to reduce command and control lead time, reduce human errors and streamline satellite asset integration. For commercial operators this allows them to maximize service capacity, increase revenue and margin, and optimize performance yield. Cognitive Space’s platform is multi-purpose, serving the needs of the Federal Government, US Department of Defense and commercial enterprises.
More information about Cognitive Space can be found at http://www.cognitivespace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom